Heart Rate vs Quality of Life: New Data Challenge the Standard Approach to Long COVID POTS

New results from the RECOVER-AUTONOMIC trial, presented by Pam R. Taub, MD, FACC, FASPC, at the American College of Cardiology 2026 Scientific Sessions (ACC.26), provide a nuanced look at the treatment of postural orthostatic tachycardia syndrome (POTS) in the wake of the COVID-19 pandemic. This multisystem disorder, characterized by orthostatic intolerance and excessive tachycardia, often results in substantial functional impairment and a reduced quality of life.¹

“In the post-COVID era we are seeing a large number of patients with POTS, and up to 31% of patients after a COVID infection develop POTS,” Taub said. “To date, there have been very few randomized controlled clinical studies in patients with conventional POTS and also long COVID POTS.”

The trial sought to determine whether ivabradine (Corlanor; Amgen), a medication that selectively lowers heart rate and norepinephrine levels without decreasing blood pressure, could alleviate the debilitating symptoms experienced by these patients. While the drug successfully achieved its physiological goal of heart rate reduction, the study’s primary end point revealed that lowering heart rate alone might not be the silver bullet patients and providers had hoped for.^1,2

The RECOVER-AUTONOMIC Study Design

RECOVER-AUTONOMIC stands as the largest randomized, double-blind, placebo-controlled study conducted in the POTS and long COVID POTS population to date. The multicenter trial enrolled 181 participants (median age 39, 85% female) who were randomized to receive either ivabradine or a placebo for a period of 3 months.^1,2

The study utilized the Orthostatic Hypotension Questionnaire (OHQ) as its primary end point to measure changes in symptoms such as dizziness, lightheadedness, fatigue, and trouble concentrating. Secondary end points included changes in heart rate during an active stand test and various quality-of-life metrics.²

Physiological Success, Symptomatic Stasis

The data presented at ACC.26 showed a clear divergence between physiological markers and patient-reported outcomes. Ivabradine produced a significant reduction in heart rate change from supine to standing compared to the placebo group (a decrease of 13.6 beats per minute versus 11.0 beats per minute, P = .007).^1,2

However, this physiological improvement did not translate to a statistically significant difference in the primary end point. The change in the OHQ composite score was –1.4 for the ivabradine group and –1.1 for the placebo group, resulting in a P-value of 0.63. Essentially, treatment with ivabradine alone did not significantly improve patient-reported orthostatic intolerance.^1,2

The Power of Coordinated Care

Perhaps the most critical finding of the trial came from a prespecified factorial analysis. Researchers found that the effect of ivabradine on symptoms differed significantly based on whether a patient received "coordinated care" or "usual care" (P-value for interaction = .004).

Patients who received both ivabradine and coordinated non-pharmacologic care—which included regular heart rate and blood pressure checks, a high-salt diet, increased fluid intake, the use of compression belts, and recommended physical activities—showed a marked improvement in their OHQ scores compared to those receiving ivabradine with only "usual care."¹

Taub’s summary emphasized that in this complex, multisystemic condition, "heart rate lowering alone may be insufficient to improve symptoms." Instead, the data suggest that ivabradine, when paired with a structured, coordinated care regimen, may offer the clinical benefit that patients need.¹

“We need to understand this population much better. Long COVID is a very complex disease. Ivabradine does lower heart rate…but lowering heart rate alone may be insufficient to improve symptoms.”¹

What This Means for Pharmacists

For pharmacists, who are often the most accessible health care providers for patients managing chronic long COVID symptoms, these data provide a vital framework for medication therapy management (MTM).

Pharmacists should be aware that while ivabradine is effective at targeting the sinoatrial node to lower heart rate without the blood-pressure-lowering side effects of β-blockers, it may not resolve the patient's entire symptomatic profile. Pharmacists can play a crucial role in counseling patients on the importance of the "coordinated care" elements used in the trial, such as high-salt intake, hydration, and the use of compression garments during upright activities.

The trial also involved weekly logs and phone calls from care coordinators. Pharmacists can assist by helping patients track their heart rate and blood pressure, ensuring they understand that symptom fluctuation is a hallmark of the "poorly understood" natural history of long COVID POTS. Finally, the researchers noted that certain phenotypes, such as patients with elevated norepinephrine levels, might still be the ideal candidates for ivabradine therapy.¹

Looking Ahead

The RECOVER-AUTONOMIC trial underscores the necessity of better clinical end points to assess interventions in the Long COVID population. Taub noted that POTS does have several phenotypes, so some patients may see more success with ivabradine than others.

“We do have blood samples stored on all these patients, and we will be doing secondary analysis to see if there are certain subsets of patients that respond better to ivabradine than others,” she said.¹

While ivabradine remains a tool in the arsenal, the study proves that multimodal therapy—combining pharmacologic heart rate control with aggressive, coordinated non-pharmacologic lifestyle interventions—is the most promising path forward for those struggling with the "debilitating symptoms" of post-COVID POTS.

REFERENCES

1. Taub PR. Impact of ivabradine on orthostatic intolerance, quality of life and heart rate in post-COVID postural orthostatic tachycardia syndrome: results from the RECOVER-Autonomic trial. Presented at: American College of Cardiology 2026 Scientific Sessions. March 28, 2026; New Orleans, LA.

2. Taub P, Shibao C, Novak P, et al. Impact of ivabradine on orthostatic intolerance, quality of life and heart rate in post-COVID postural orthostatic tachycardia syndrome: results from the Recover-Autonomic trial. Presented at: American College of Cardiology 2026 Scientific Sessions. March 28, 2026; New Orleans, LA. https://cattendee.abstractsonline.com/meeting/21230/presentation/18552